Thymosin-inducible 'null' cells in atopic eczema

Area of Science:

• Immunology
• Dermatology
• Pediatrics

Background:

• Atopic eczema is a common inflammatory skin condition.
• T-lymphocyte levels and their role in immune regulation are crucial for understanding eczema pathogenesis.

Purpose of the Study:

• To investigate peripheral blood T-lymphocyte levels in children with atopic eczema.
• To explore the effect of thymosin on T-lymphocyte counts in eczema patients.
• To examine correlations between eczema severity, immune markers, and T-cell subsets.

Main Methods:

• Comparative study of 30 children with atopic eczema and 30 age-matched healthy controls.
• Measurement of peripheral blood T-lymphocyte counts.
• In vitro assessment of thymosin's effect on T-lymphocyte levels.
• Correlation analysis between clinical eczema severity and immunological parameters (eosinophilia, IgE, T-lymphocyte counts).

Main Results:

• Children with atopic eczema exhibited significantly lower mean peripheral blood T-lymphocyte counts (1,197/mm³) compared to healthy controls (1,702/mm³).
• In vitro treatment with thymosin normalized the T-lymphocyte levels in the eczema group.
• Eczema severity positively correlated with eosinophilia and hyperimmunoglobulin E, but not T-lymphocytopenia.
• Thymosin-inducible T-cell (Ti) counts showed a correlation with plasma IgE levels.

Conclusions:

• A T-cell deficiency, potentially involving immature suppressor T cells, may contribute to the pathogenesis of atopic eczema by impairing IgE regulation.
• Thymosin demonstrates potential as a therapeutic agent for atopic eczema by modulating T-cell function and IgE responses.